LAVAL, QC, April 21, 2026 /CNW/ - In recognition of AML World Awareness Day, Servier Canada is highlighting the progress made in precision medicine for Acute Myeloid Leukemia (AML). With TIBSOVO(R) ...

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

The Hematology Society of Taiwan yesterday said acute myeloid leukemia (AML), a fast-growing cancer of the blood and bone marrow, can progress quickly and aggressively and urged the government to ...

SELLAS Life Sciences (SLS) is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst.

PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in R/R High-Risk Myelodysplastic Syndrome & R/R Acute Myeloid Leukemia ...

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding ...

A new analysis by researchers at The University of Texas MD Anderson Cancer Center demonstrates that a combination therapy ...

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML ...

Kyowa Kirin and Kura Oncology have initiated a Japanese Phase II registrational trial of ziftomenib, an oral menin inhibitor, in adults with relapsed or refractory NPM1‑mutated acute myeloid leukemia.

Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving ...

LYT-200 plus HMA at 12 mg/kg delivered 45.5% ORR in 11 R/R HR-MDS patients, including 27.3% CRs, despite 100% prior HMA ...

Kyowa Kirin and Kura Oncology have started a Japanese phase II trial of ziftomenib, an oral menin inhibitor, for adults with relapsed or refractory NPM1‑mutated acute myeloid leukemia. The open‑label ...